Therapy News and Research

RSS

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of the treatment plan.

11 Dec 2023

Unmasking the culprits behind long-term arm problems in breast cancer patients

A new review paper was published in Oncotarget's Volume 14 on December 1, 2023, entitled, "Risk factors for long-term arm morbidities following breast cancer treatments: A systematic review."

11 Dec 2023

Study reveals genetic roots of hodgkin lymphoma, offering hope for new treatments

A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others who are likely to experience a disease recurrence - potentially letting some patients who are predicted to have favorable outcomes forgo lengthy treatment.

11 Dec 2023

MIT scientists develop nanoparticles to reduce inflammation in the brain

Some Covid-19 vaccines safely and effectively used lipid nanoparticles (LNPs) to deliver messenger RNA to cells. A new MIT study shows that different nanoparticles could be used for a potential Alzheimer's disease (AD) therapy.

11 Dec 2023

New combinations and targeted therapies for acute myeloid leukemia on the horizon

The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.

11 Dec 2023

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

11 Dec 2023

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

New organoid model could revolutionize neuroendocrine tumor research

The Organoid Group (Hubrecht Institute) and the Rare Cancers Genomics Team (IARC/WHO) found a way to grow samples of different types of neuroendocrine tumors (NETs) in the lab.

11 Dec 2023

Natural compound activates macrophages to fight resistant tuberculosis bacteria

Tuberculosis (TB) is a prevalent infectious disease that affects millions of people each year. It was previously the leading cause of death from a single pathogen before the COVID-19 pandemic.

11 Dec 2023

From surviving to thriving: a framework for long-term success in people with HIV

NewsMedical spoke to Lisa Sterman, Global Executive Director, Global HIV Medical Affairs, Gilead Sciences, about the recently published LTS framework, recently highlighted at the opening ceremony of the 19th European AIDS Conference, which takes a person-centric approach to the HIV treatment journey.

From Gilead Sciences, Inc. 11 Dec 2023

Researchers develop novel exosome-based drug delivery system to treat Alzheimer's disease

A research team led by Hong Kong Baptist University (HKBU) has developed a novel drug delivery system for Alzheimer’s disease (AD).

11 Dec 2023

Phase 2 trial data shows safety, tolerability and efficacy of imlifidase in GBS patients

Hansa Biopharma today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures.

11 Dec 2023

Therapy News and Research

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

Unmasking the culprits behind long-term arm problems in breast cancer patients

Study reveals genetic roots of hodgkin lymphoma, offering hope for new treatments

MIT scientists develop nanoparticles to reduce inflammation in the brain

New combinations and targeted therapies for acute myeloid leukemia on the horizon

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

New organoid model could revolutionize neuroendocrine tumor research

Natural compound activates macrophages to fight resistant tuberculosis bacteria

From surviving to thriving: a framework for long-term success in people with HIV

Researchers develop novel exosome-based drug delivery system to treat Alzheimer's disease

Phase 2 trial data shows safety, tolerability and efficacy of imlifidase in GBS patients

Small molecule applications of process Raman spectroscopy

Varied early symptoms of bacterial meningitis in adults and children highlight diagnostic challenges

Breakthrough in pancreatic cancer treatment: Inhibiting specific enzymes slows tumor progression

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News